SCHEMBL5842538

SCHEMBL5842538

FC1=CC=CC(Br)(c2ccccc2)C1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.32
MAOA P21397 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17866314 0.79 HDAC9 (0.36)
SCHEMBL9720104 0.77 SLC6A3 (0.35)
SCHEMBL11822773 0.76 HDAC1 (0.34)
SCHEMBL11820715 0.68 NPC1 (0.36) MAOBMAOA
SCHEMBL276639 0.67 HDAC4 (0.32)
SCHEMBL29223962 0.67 CA1 (0.33)
SCHEMBL6485450 0.66
SCHEMBL8449213 0.66
SCHEMBL6999700 0.64 NPY5R (0.30)
SCHEMBL31123505 0.63 MAOB (0.32) MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110746983-B Achiral side methyl alkyl terphenyl liquid crystal compound, preparation method, liquid crystal composition and application 武汉轻工大学 2021-09-17 CN disclosed
CN-110746983-A Achiral side methyl alkyl terphenyl liquid crystal compound, preparation method, liquid crystal composition and application 武汉轻工大学 2020-02-04 CN disclosed
US-7119203-B2 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION (US) 2006-10-10 US disclosed
US-20050209278-A1 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION 2005-09-22 US disclosed
US-20050009838-A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209278-A1 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors MMP1, PREP, MMP3 MAOB 1252/4885MAOA 500/4885
US-20050009838-A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors MMP1, PREP, MMP3 MAOB 1252/4885MAOA 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.